Market Overview

Infinity Announces Updated Phase 1 Data of IPI-145 in iNLH at ASH 2013


Infinity Pharmaceuticals (NASDAQ: INFI) today announced updated Phase 1 data from an ongoing study of IPI-145, its oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, in patients with
relapsed/refractory indolent non-Hodgkin lymphoma (iNHL), a potentially fatal hematologic malignancy (blood cancer). Data from the study showed
that IPI-145 was clinically active, with an overall response rate of 73 percent, including three complete responses, among patients receiving
IPI-145 dosed at ≤ 25 mg twice daily (BID). Data also showed that 53 percent of patients remained progression free for over one year. These
data support DYNAMO, the ongoing Phase 2 study of IPI-145 in patients with refractory iNHL. These findings were presented today at the 55th
Annual Meeting of the American Society of Hematology (ASH).#ASH13

See full press release

Posted-In: News Guidance Management Global


Related Articles (INFI)

View Comments and Join the Discussion!